Telomir Publishes Telomir-Zn AMD Preclinical Findings
MIAMI, Fla. — September 17, 2026 Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn...
Triple-Negative Breast Cancer
Advertisement
Telomir Advances Telomir-Zn in Human and Canine Osteosarcoma
MIAMI, Fla. — September 14, 2026 Telomir Pharmaceuticals, Inc. announced new research conducted with The Ohio State University College...
Context Therapeutics Doses First Patient in CT-202 Phase 1
PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...
CoRegen Wins FDA IND Clearance for CRG-150
HOUSTON, July 7, 2026 CoRegen, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance...
Anixa Wins First Korean Patent for Breast Cancer Vaccine
SAN JOSE, Calif., June 29, 2026 Anixa Biosciences, Inc. announced that the Korean Ministry of Intellectual Property (MOIP) has...
Advertisements
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
Datroway by AstraZeneca Approved as First TROP2 ADC for TNBC
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
Mabwell 9MW2821 Advances to Phase III in TNBC Trial
SHANGHAI, April 23, 2026 Mabwell has announced the initiation of a Phase III clinical trial for its proprietary Nectin-4-targeting...
Telomir Acquires TELI to Secure Global Telomir-1 Rights
MIAMI, FL, April 24, 2026 Telomir Pharmaceuticals has announced the successful completion of its acquisition of TELI Pharmaceuticals, securing...
Iza-bren Meets Dual Endpoints in Phase III TNBC
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026 SystImmune, Inc. and Bristol Myers Squibb announced positive interim topline results...
Advertisement
